ROCHESTER, Minn.--(BUSINESS WIRE)--RION, at the forefront of exosome innovation and therapeutic application, has officially commenced a Phase 1b study aimed at assessing the efficacy and safety of ...

Researchers evaluated the real-world efficacy of statewide doxycycline post-exposure prophylaxis against common sexually transmitted infections.

Having antiretrovirals on hand to take as post-exposure prophylaxis after potential HIV exposure, an approach known as PEP-in-pocket, or PIP, is a feasible prevention option, especially for people who ...

Taking a dose of the oral antibiotic doxycycline after a high-risk sexual encounter has dramatically reduced the incidence of sexually transmitted infections (STIs) in places where the strategy is ...

INTENT Biologics, a clinical-stage biotechnology company developing PEP Biologic as the first-in-class exosome-based biologic therapies for serious conditions with significant unmet medical need, ...

Please provide your email address to receive an email when new articles are posted on . Roughly one-third of people eligible for HIV post-exposure prophylaxis did not receive a prescription. Fewer ...

ROCHESTER, Minn.--(BUSINESS WIRE)--RION, a clinical-stage regenerative medicine company at the forefront of exosome-based therapeutics, announced today that it has completed patient enrollment in its ...